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AutophagyReperfusion injury of the heart is a severe complication of angioplasty treatment of acute myocardial ischemia,
for which no therapeutics are currently available. The present study aimed to identify whether and how a
novel protein, netrin-1, induces cardioprotection in vivo during ischemia/reperfusion (I/R) injury. Wild type
(WT) C57BL6/J mice were subjected to a 30 min coronary occlusion followed by a 24 h reperfusion with vehicle
(normal saline), netrin-1, UO126 (MEK1/2 inhibitor), PTIO (nitric oxide/NO scavenger), netrin-1/UO126 or
netrin-1/PTIO intraventricularly. Some were injected of netrin-1 via tail vein. Netrin-1 at 5 μg/kg induced a
substantial reduction in infarct size (19.7 ± 5.0% from 41.3 ± 1.8% in the controls), and markedly improved car-
diac function as measured by ejection fraction and fractional shortening from echocardiography. Experiments
with mice deﬁcient in netrin-1 receptor DCC (deleted in colorectal cancer, DCC+/−), or reperfusion with
netrin-1/UO126 or netrin-1/PTIO, attenuated the protective effects of netrin-1, implicating intermediate roles
of DCC, ERK1/2 and NO. Netrin-1 induced phosphorylation of ERK1/2 and eNOS was abolished in DCC+/−
mice. Electron spin resonance (ESR) determination of NO production from isolated left ventricles demonstrated
that netrin-1 improves NO bioavailability, which was attenuated by UO126 or in DCC+/−mice, suggesting
upstream roles of DCC and ERK1/2 in NO production. Netrin-1 further reduced mitochondrial swelling and
mitochondrial superoxide production, which was absent when co-treated with PTIO or UO126, or in DCC+/−
mice, indicating critical roles of DCC, ERK1/2 and NO in preserving mitochondrial integrity. In a permanent
coronary ligation model of myocardial infarction (MI) to assess post-MI remodeling, netrin-1 abolished the
marked increase in autophagy. In summary, our data demonstrate robust cardioprotective effect of netrin-1
in vivo, as shown by reduced infarct size and improved cardiac function. Mechanistically, this protection is
mediated by netrin-1 receptor DCC, and NO dependent preservation of mitochondria. This work clearly
establishes a therapeutic potential of netrin-1 for acute treatment of MI, perhaps also for chronic post-MI
remodeling. This article is part of a Special Issue entitled: Autophagy and protein quality control in
cardiometabolic diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Acute myocardial infarction (MI) is one of the leading causes of
morbidity and mortality in the adult population that strikes 7.6 million
American adults, or about one person every 44 seconds in the United
States [1]. The mainstay of current therapy for acute MI is the
restoration of blood ﬂow (reperfusion) to the affected area through
angioplasty, sometimes in conjunction with thrombolytic therapyy and protein quality control in
1 310 825 0132.to remove/prevent thrombi formation. However, the reperfusion of
ischemic tissue can itself lead to severe myocardial damage [2].
Intensive research efforts have been focused on the amelioration of
various pathophysiological components of ischemia/reperfusion (I/R)
injury to limit the extent of cell death [3]. However, data accumulated
in the past 20 years have shown that there is no clinically effective
therapy for the prevention of I/R injury. Currently, while there are
some potential agents under trials for this condition, such as cyclospor-
ine A, there are no clinically approved treatments for the prevention of
cardiac I/R injury.
Netrin-1 has been originally identiﬁed as a midline-derived
chemoattractant that guides axons to the midline during development
[4–6]. Its functions are mainly mediated by the receptors deleted in co-
lorectal cancer (DCC) and the uncoordinated-5 (UNC5) families [7–10].
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[11–13]. In our laboratory, we have shown that netrin-1 can induce an-
giogenesis through an increase in endothelial nitric oxide (NO) synthase
(eNOS) activation and NO production [13]. Further, we have shown that
netrin-1 induces cardioprotection against I/R via a DCC/ERK1/2/eNOS/
NO/DCC feed-forward pathway, using an ex-vivomodel of Langendorff
perfused heart [14].
In the present studywe aimed to examinewhether and hownetrin-1,
potentially via production of NO, is cardioprotective in vivo. We ex-
amined whether netrin-1 improves cardiac function by measuring
ejection fraction and fraction shortening using echocardiography at
day 1 and day 3 after reperfusion, using animals treated with
netrin-1 both intraventricularly and intravenously via the tail vein.
Treatment with netrin-1 dose-dependently reduced infarct size and
improved cardiac functionmeasured by echocardiography. Experiments
using pharmacological inhibitors (UO126 as ERK1/2 inhibitor, PTIO asNO
scavenger), animals deﬁcient in netrin-1 receptor DCC, and experiments
measuring p-eNOS, p-ERK1/2, NADPH oxidase isoform 4 (NOX4)
expression and activity, levels of NO and superoxide by electron spin
resonance (ESR), as well as mitochondrial damage via mitochondrial
swelling, showed that mechanistically netrin-1's cardioprotective effect
is mediated by DCC and NO dependent suppression of NOX4-derived
oxidative stress, aswell as protection ofmitochondria. Using an addition-
al permanent myocardial infarction (MI) model we have also observed
robust effects of netrin-1 in attenuating autophagy. This work clearly
shows the efﬁcacy of netrin-1 as a potent cardioprotective agent against
I/R damage in vivo, hence the potential as a novel therapeutic for acute
treatment of MI, or perhaps also for chronic post-MI remodeling.
2. Materials and methods
2.1. Materials
Puriﬁed recombinant mouse netrin-1 (R&D Systems, Minneapolis,
MN, USA) was administered at doses ranging from 1 to 50 μg/kg, dis-
solved in normal saline, via injection into the LV lumen at the onset of
reperfusion. Some mice were subjected to tail vein injection with
netrin-1 (5 μg/kg) also immediately at the onset of reperfusion.
UO126, a MEK1/2 inhibitor (200 μg/kg, dissolved in DMSO b 0.01%),
and PTIO (1 mg/kg, dissolved in normal saline), a speciﬁc NO chelator,
were purchased from Sigma-Aldrich in highest purity (St. Louis, MO,
USA), and administered via injection into the LV lumen at the onset of
reperfusion.
Polyclonal antibodies speciﬁc for phosphorylated and total forms of
ERK1/2 and eNOS were obtained from Cell Signaling Technology (CST,
Danvers, MA, USA). NOX4 antibody was purchased from Abcam
(Abcam, Cambridge, MA, USA). Anti-actin antibody, and other
chemicals in highest purity were purchased from Sigma-Aldrich
(Sigma-Aldrich, St. Louis, MO, USA).
2.2. Animals
Male C57BL6/J mice (6–8 weeks old) were obtained from the
Jackson Laboratories (Bar Harbor, ME). The DCC+/−breeding colony
was kindly provided by Dr. Marc Tessier-Lavigne from The Rockefeller
University. Mice were housed under pathogen-free conditions. The
use of animals and experimental procedures were approved by the
Institutional Animal Care and Usage Committee at the University of
California Los Angeles (UCLA).
2.3. In vivo murine model of myocardial ischemia–reperfusion injury
Brieﬂy, mice were pre-medicated with heparin (1000 IU/kg, i.p.)
and anesthetized 5 min later with sodium pentobarbital (60 mg/kg,
i.p.). An additional dose of pentobarbital (50 μL; 20 mg/kg, i.p.) was
given as needed to maintain anesthesia. After an adequate depth ofanesthesia is attained the mouse is ﬁxed in a supine position with
tape. Mice were then orally intubated and ventilated mechanically
with a Harvard Apparatus Rodent Ventilator (model 845). A mix of ox-
ygen and carbon dioxide (95:5%) was supplied, and body temperature
was monitored using a rectal probe thermometer and controlled with
a heating pad. Left thoracotomy was performed in order to reveal the
left coronary artery (LCA). Myocardial ischemia was achieved by tying
a 7-0 Prolene thread around the LCA,whichwas then subsequently con-
ﬁrmed by the occurrence of regional cyanosis. The LCA was completely
occluded for 30min, and reperfusionwas initiated by removal of the 7-0
suture. Reperfusion was conﬁrmed by visualization of a hyperaemic re-
sponse. The chest wound was then reapproximated, and mice were
extubated and allowed to recover with supplemental oxygen until
mobile. All mice received buprenorphine (0.1 mg/kg) subcutaneously
to minimize pain. The I/R protocol and the experimental procedures
involving treatments with netrin-1 and pharmacological inhibitors are
summarized in Suppl. Fig. 1.
2.4. Infarct size analysis
After 24 h reperfusion, mice were given heparin (1000 IU/kg, i.p.),
after which they were anesthetized with sodium pentobarbital
(60 mg/kg, i.p.). The coronary artery was re-occluded at the original
site of occlusion, while a solution of Evan blue dye (5% solution) was
injected through the apex. The auricle and the right ventricle were re-
moved and the left ventricle (LV) was excised into 6 slices using a
mouse heart matrix (Harvard Apparatus, Holliston, MA, USA). Before
2,3,5-triphenyltetrazolium chloride (TTC) incubation, each slice is
photographed in order to determine the area at risk (AAR) identiﬁed
by the absence of Evans blue staining. The infarct area (IA) was identi-
ﬁed by incubating each slice with TTC (1% solution, 5 min at 37 °C).
The AAR identiﬁed by the absence of Evans blue stainingwas expressed
as a percentage of the left ventricleweight and the IAwas expressed as a
percentage of the AAR. Each transverse slice was ﬁxed in 10% neutral
buffered formaldehyde and 1 h later, weighed and photographed. The
different areas (AAR, IA, LV circumference, LV cavity circumference)
were measured by computerized videoplanimetry (NIH ImageJ-1.37),
and from these measurements infarct size was calculated as a percent-
age of the AAR.
2.5. Echocardiography
Cardiac morphology and function were assessed using anesthetized
(0.6–0.8% isoﬂurane in 95% oxygen, heart rate: 420–450 beats/min)
mice by transthoracic echocardiography (Vevo2100 echocardiograph
with MS-400 probe, VisualSonics, Toronto, Ontario, Canada). Two-
dimensional images and M-mode tracing were recorded from the
parasternal short axis view at the midpapillary level to determine the
left ventricular internal diastole diameter (LVID:D) and left ventricular
internal systolic diameter (LVID:S). Fractional shortening and ejection
fraction were calculated directly from the short axis view of heart
contraction.
2.6. Western blot analysis
At the end of the 10 min or 30 min of reperfusion, the heart was
removed and the LV was immediately frozen in liquid nitrogen.
Subsequently, the tissue was powderized and homogenized in lysis
buffer (Tris 50 mmol/L, EDTA 0.1 mmol/L, EGTA 0.1 mmol/L, protease
inhibitor cocktail, phosphatase inhibitors cocktail 2 and 3, pH 7.4). The
homogenates were vortexed and centrifuged at 17,600 g for 30 min at
4 °C. The supernatantswere used forWestern blot analysis. Protein con-
centrations were determined by the Bradford method using bovine
serum albumin as a standard (Bio-Rad protein assay kit, Bio-Rad,
Hercules, CA, USA).
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buffer containing β-mercaptoethanol for 5 min. Proteins (30 μg/lane)
were separated by a 10% SDS–PAGE gel, transferred to nitrocellulose
membranes (Hybond™,GE Health Care, Piscataway, NJ, USA) and
probed overnight with primary antibodies for phospho-ERK1/2 (Thr
202/Tyr204), phospho-eNOS (Ser1177), NOX4, total ERK1/2, total
eNOS, and actin. Blots were washed and then incubatedwith secondary
antibody conjugated to horseradish peroxidase (Bio-Rad laboratories,
Hercules, CA, USA) prior to incubation with ECL reagent (Pierce,
Rockford, IL, USA) and exposed to an autoradiography ﬁlm (Hyblot CL,
Denville scientiﬁc, Metuchen, NJ, USA). Bands of interest were scanned
and quantiﬁed in a blinded manner using gel analysis software NIH
ImageJ-1.37.
2.7. Electron spin resonance detection of nitric oxide radical
Bioavailable nitric oxide radical (NO) from LV tissues was detected
using electron spin resonance (ESR) as described [13–16]. In brief, the
LV heart homogenates were incubated with equal volume of freshly
prepared NO-speciﬁc spin trap Fe2+(DETC)2 colloid (0.5 mmol/L) for
60 min, in the presence of calcium ionophore A23187 (10 μmol/L).
Gently collected homogenates suspensions were snap-frozen in liquid
nitrogen and loaded into a ﬁnger Dewar for analysis with an eScan elec-
tron spin resonance (ESR) spectrophotometer (Bruker) at the following
settings: center ﬁeld, 3410; ﬁeld sweep, 100 G; microwave frequency,
9.73 GHz; microwave power, 13.26 mW; modulation amplitude, 9.82
G; 512 points resolution and receiver gain, 356.
2.8. Electron spin resonance measurement of mitochondrial superoxide
production
For isolation of heart mitochondria, fresh left ventricular tissues
were placed in buffer containing 220 mmol/L mannitol, 70 mmol/L su-
crose, 10 mmol/L HEPES, 1 mmol/L EGTA (Sigma-Aldrich, St. Louis, MO,
USA), pH 7.4 at 4 °C. The tissuesweremincedwith scissors and homog-
enized on ice using a Teﬂon Potter homogenizer andwere centrifuged at
1000 g for 5 min. Supernatants were centrifuged at 10,000 g for 10min.
The ﬁnal pellets were resuspended in homogenization buffer including
0.01 mmol/L EGTA. Protein concentrations were determined by the
Bradford method using bovine serum albumin as a standard (Bio-Rad
protein assay kit, Bio-Rad, Hercules, CA, USA). The speciﬁc superoxide
spin trap methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine (CMH,
500 μmol/L, Alexis) solution was prepared freshly in nitrogen gas
bubbled Krebs/HEPEs buffer containing diethyldithiocarbamic acid
(DETC, 5 μmol/L Sigma) and deferoxamine (25 μmol/L, Sigma). Three
microliters of the isolated mitochondria was then mixed with spin
trap solution and loaded into glass capillary (total volume of 100 μL,
Fisher Scientiﬁc) for analysis of superoxide signal (CM• formed after
trapping O2•−) using eScan ESR spectrometer (Bruker) at the following
settings: center ﬁeld, 3410; ﬁeld sweep, 100 G; microwave frequency,
9.73 GHz; microwave power, 13.26 mW; modulation amplitude, 9.82
G; 512 points resolution and receiver gain, 356. The ﬁnal superoxide
value was normalized by the amount of mitochondrial protein loaded.
2.9. Mitochondrial swelling assay
The activation of themitochondrial permeability transition porewas
determined by Ca2+-induced swelling of isolated cardiacmitochondria.
Opening of the pore causes mitochondrial swelling, which was mea-
sured spectrophotometrically as a decrease in absorbance at 540 nm.
Isolated cardiac mitochondria (30 μg) were incubated for 1 min in the
swelling buffer, which contained 250 mmol/L sucrose, 10 mmol/L
Tris·HCl (pH 7.4) and energized with 2 mmol/L of succinate, to a ﬁnal
protein concentration of 0.3 mg/L. Pore opening was induced by
250 μmol/L of CaCl2 and the decrease in absorbance was measured at
540 nm every minute for 20 min using a 96-well plate.2.10. NOX4 activity assay
NOX4 activity was determined using isolated membrane fraction.
For the isolation of the membrane fraction, hearts were isolated from
animals after 10 min of reperfusion, then homogenized on ice in a
glass homogenizer in lysis buffer as described above. The homogenate
was serially centrifuged at 1200 g for 5 min, 22,000 g for 20 min, and
13,700 g for 90 min at 4 ºC. The ﬁnal pellet was resuspended in lysis
buffer (100 μL per heart). Superoxide production was measured as
described above, with 10 μg protein loaded as measured using the
Bradfordmethod. Kinetic NADPH-driven (100 μmol/L ﬁnal concentration)
NOX4 activity wasmeasured in the presence or absence of Fulvene-5, a
speciﬁc NOX4 inhibitor (kindly provided by Dr. Jack L. Arbiser from
Emory University) [17].2.11. Animal model of MI and assessment of autophagy
MaleC57BL/6mice (8–10 weeks old)wereused to inducemyocardial
infarction (MI) by permanent left anterior descending (LAD) coronary
artery ligation. Two days before the surgery, the mice were infused
with netrin-1 (15 ng/kg per day) or vehicle using subcutaneously im-
planted osmotic pumps (14 days, Durect Corp). Then the mice were
anesthetizedwith pentobarbital (50 mg/kg, i.p.) and ﬁxed in the supine
position with positive pressure respiration. The left thorax was opened
and the LAD coronary artery was located and ligated with a 8–0 silk su-
ture 2–3mm from origin. The ligationwas deemed successful when the
anterior wall of the LV turned pale. After the ligation, the chest was
closed in layers, and the mice were removed from the ventilator when
awake. Sham-operated animals were subjected to similar surgery,
except that no ligature was placed.
Two weeks later, isolated hearts were subjected to protein
isolation and western blotting analysis as described earlier, using
speciﬁc antibodies to LC3 (1:3000, Sigma) and β-actin. LC3 expres-
sion levels were analyzed using ImageJ program and normalized by
β-actin.2.12. Statistical analysis
All data are presented as mean ± SEM. Comparisons between two
groups were made using student's t-test, while multiple comparisons
with more than two groups were made using ANOVA followed by
Newman–Keuls's post-hoc test. Statistical signiﬁcance was deﬁned as
p b 0.05.3. Results
3.1. Netrin-1 attenuates I/R induced myocardial infarction in vivo
To examine whether netrin-1 administration is effective in in-
ducing cardioprotection against I/R damage in vivo, wild type
C57BL6J mice were subjected to a 30 min ischemia by coronary oc-
clusion, followed by a 24 h reperfusion. Netrin-1 or vehicle (normal
saline) was injected into the LV lumen at the onset of reperfusion at
doses ranging from 1 to 50 μg/kg. Mice receiving vehicle injection
displayed a 41.3 ± 1.8% infarct size per area at risk (Inf/AAR), and
a 17.1 ± 1.5% infarct size per LV size (Inf/LV). Treatment with
netrin-1 at 5 μg/kg and 10 μg/kg signiﬁcantly decreased infarct
size (19.7 ± 5.0% and 29.9 ± 1.5% respectively for Inf/AAR; and
8.1 ± 2.0% and 11.9 ± 0.8% respectively for Inf/LV, Fig. 1). At the
high dose of 50 μg/kg, the cardioprotective effect of netrin-1 disap-
peared (47.0 ± 1.0% for Inf/AAR, and 20.1 ± 0.6% for Inf/LV). The
percent AAR per LV (AAR/LV) was similar among all study groups,
indicating similar severities of myocardial ischemia.
I/R (vehicle) I/R+Netrin-1 
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I/R+Netrin-1 
(1µg/kg)
I/R+Netrin-1 
(10 µg/kg)
I/R+Netrin-1 
(50 µg/kg)
***p<0.001 vs. Control I/R (Vehicle), n=7/group
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Fig. 1.Netrin-1 attenuates I/R induced myocardial infarct in vivo. Myocardial infarction was induced by a 30min left coronary artery (LCA) ligation followed by a 24 h reperfusion
in wild type C57BL6 mice in vivo. The mice were treated at the onset of reperfusion with either netrin-1 (1–50 μg/kg) or vehicle (normal saline). Evans blue was used to visualize
the non-ischemic area. A) Representative TTC-stained heart slices from I/R (vehicle) group, and I/R+netrin-1 (1–50 μg/kg) groups. The white area indicates infarct zone, while
the blue area indicates non-infarcted area. The red and white areas represent area at risk. B) Infarct size analyzed by: percentage of area at risk divided by left ventricular (AAR/
LV), infarct size divided by area at risk (Inf/AAR), and infarct size divided by left ventricular (Inf/LV). The results are presented as mean ± SEM. The number of animal per group
was seven. ⁎⁎⁎p b 0.001 vs. control I/R (vehicle).
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To further validate netrin-1's cardioprotective properties in vivo, we
measured LV dilatation (LVID:d and LVID:s) and cardiac function via
echocardiography on animals that underwent I/R injury. The results,
shown in Fig. 2A and C, illustrated that both fractional shortening and
ejection fraction were signiﬁcantly decreased in vehicle treated hearts
at both 1 and 3 days after I/R. Treatment with netrin-1 through the LV
resulted in signiﬁcantly increased ejection fraction and fractional
shortening, suggesting an improvement in cardiac function. Fig. 2AFig. 2. Intraventricular and intravenous delivery of netrin-1 improves cardiac function afte
perfused for 24 h or 72 h after a 30 min left coronary artery (LCA) ligation. Left ventricular
S), ejection fraction and fractional shortening were measured. A) Representative echocard
of reperfusion. B) Grouped data for left ventricular internal dimension (LVID) during systol
3 days) and diastole (⁎p b 0.05 vs. I/R(vehicle)-1, #p b 0.05 vs. I/R(vehicle)-3 days) for mic
fractional shortening data for mice with netrin-1 injected through LV. ⁎⁎⁎p b 0.001 vs. I/R (vehic
diography data from mice with netrin-1 (5 μg/kg) injected through tail vein. E) Grouped LVID
3 days) and diastole (⁎p b 0.05, ⁎⁎p b 0.01 vs. I/R(vehicle)-1 day, #p b 0.05, ##p b 0.01 vs. I/R(veh
F) Grouped ejection fraction (⁎p b 0.05, ⁎⁎p b 0.01, ⁎⁎⁎p b 0.001 vs. I/R (vehicle)-1 day, ##p b 0.01
I/R (vehicle)-1 day, #p b 0.05, ###p b 0.001 vs. I/R (vehicle)-3 days) from mice with netrin-1 (5and B indicated that LV structures were signiﬁcantly improved in
netrin-1 treated hearts at both 1 and 3 days after I/R. These data show
that netrin-1 can functionally rescue I/R injured heart in vivo.
Additionally, separate experiments were performed where the
treatment of vehicle or netrin-1 was injected through the tail vein.
The results, shown in Fig. 2D and F, indicate a similar trend in the
recovery of cardiac function as compared to LV injected hearts. Like-
wise, LV structures were also improved as compared to LV injected
hearts. This shows that netrin-1 is effectively protective against I/R
injury when given through a more easily accessible route.r I/R injury in vivo. Echocardiography was performed on wild type C57BL6/J mice re-
internal diastole diameter (LVID:D), left ventricular internal systolic diameter (LVID:
iography data from mice with netrin-1 (5 μg/kg) injected through the LV at the onset
e (⁎p b 0.05, ⁎⁎p b 0.01 vs. I/R(vehicle)-1 day, ##p b 0.01, ###p b 0.001 vs. I/R(vehicle)-
e with netrin-1 injected through LV, n= 3–7/group. C) Grouped ejection fraction and
le)-1 day, ###p b 0.001 vs. I/R (vehicle)-3 days, n= 3–7/group. D) Representative echocar-
during systole (⁎⁎p b 0.01 vs. I/R(vehicle)-1 day, ##p b 0.01, ###p b 0.001 vs. I/R(vehicle)-
icle)-3 days) frommice with netrin-1 (5 μg/kg) injected through tail vein, n= 3–9/group.
, ###p b 0.001 vs. I/R (vehicle)-3 days) and fractional shortening (⁎p b 0.05, ⁎⁎⁎p b 0.001 vs.
μg/kg) injected through tail vein, n= 3–9/group. Data are presented as mean ± SEM.
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DSham Saline, injected through tail vein Netrin-1, injected through tail vein
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Fig. 2 (continued).
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Fig. 3. Netrin-1-mediated cardioprotection in vivo is DCC dependent. Myocardial in-
farction was induced by a 30 min left coronary artery (LCA) ligation followed by a
24 h reperfusion in DCC+/+mice and DCC+/−mice. The mice were injected of
5 μg/kg netrin-1 at the onset of reperfusion. Netrin-1 yielded signiﬁcant protection
in DCC+/+and not in DCC+/−animals. A) Representative TTC-stained heart slices
from DCC+/+, I/R+netrin-1 group, and DCC+/−, I/R+netrin-1 group. B) Infarct
size analyzed by percentage of area at risk divided by left ventricle (AAR/LV), infarct
size divided by area at risk (Inf/AAR), and infarct size divided by left ventricle (Inf/LV).
The results are represented as mean ± SEM. ⁎⁎⁎p b 0.001 vs. DCC+/+, I/R+netrin-1,
n = 7/group. I/R+UO126 I/R+netrin-1.
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To examine whether netrin-1's cardioprotective effect is dependent
upon its receptor deleted in colorectal cancer (DCC), DCC+/+and
DCC+/−mice were subjected to a 30 min of myocardial ischemia
followed by a 24 h of reperfusion. Mice received either 5 μg/kg netrin-
1 or vehicle at the onset of reperfusion. In DCC+/−mice, netrin-1 failed
to reduce infarct size (44.4 ± 1.4% vs. 24.7 ± 3.2% in DCC+/+mice for
Inf/AAR, and 18.3 ± 0.6% vs. 11.0 ± 1.2% in DCC+/+mice for Inf/LV)
(Fig. 3). AAR/LV was similar for both groups. These data clearly impli-
cate an intermediate role of DCC in mediating netrin-1 induced
cardioprotection in vivo.3.4. Role of NO and ERK1/2 in netrin-1 induced cardioprotection in vivo
We have previously identiﬁed a DCC-ERK1/2-eNOS-NO pathway in
mediating netrin-1's potent cardioprotective effect against I/R injury
ex-vivo[14]. Here, we examined whether similar mechanisms underlienetrin-1 induced cardioprotection in vivo. Mice were subjected to a
30 min myocardial ischemia, followed by a 24 h reperfusion, and
injected with vehicle (normal saline); netrin-1; UO126 (MEK1/2 inhib-
itor); PTIO (NO scavenger); netrin-1/UO126, or netrin-1/PTIO (at same
doses described earlier) at the onset of reperfusion. As shown in Fig. 4,
UO126 or PTIO alone had no signiﬁcant effect on infarct size. Co-
treatment of UO126 or PTIO with netrin-1 completely prevented
netrin-1's cardioprotective effect, as shown by the infarct sizemeasure-
ments (Fig. 4). These data indicate that ERK1/2 and NO are required for
netrin-1 induced cardioprotection in vivo. AAR/LV was similar for both
groups (Fig. 4), showing that I/R injury was comparable.
3.5. Netrin-1 activation of ERK1/2 and NO in vivo is DCC dependent
As shown above, ERK1/2 and NO are involved in netrin-1 induced
cardioprotection against I/R damage in vivo. Here, we examined wheth-
er mechanistically they lie downstream of DCC. Western blotting of p-
ERK1/2 and p-eNOS was performed from DCC+/+ and DCC+/−mice
subjected to a 30 min ischemia followed by a 24 h reperfusion, and
treated at the onset of reperfusion with vehicle (normal saline) or
netrin-1. In DCC+/+mice, treatment with netrin-1 signiﬁcantly acti-
vated ERK and eNOS in cardiac tissue under I/R. This activation was
abolished in DCC+/−mice, where netrin-1 resulted in no signiﬁcant
change in ERK and eNOS activation compared with untreated controls
(Fig. 5A, B). These results demonstrate that netrin-1 activation of
ERK1/2 and eNOS activation in vivo are dependent on DCC. We also ex-
amined iNOS expression after reperfusion of netrin-1 (Fig. 5C), which
showed no signiﬁcant changes between I/R or I/R/netrin-1 group with
sham condition. This further support the observation that eNOS is the
major NOS isoform that is responsible for cardioprotective effect of
netrin-1.
3.6. Netrin-1 induces NO production in vivo in aDCC and ERK1/2 dependent
manner
Data described above suggest that both ERK1/2 and eNOS activation
lie downstream of DCC. We next measured NO directly using ESR to elu-
cidate the exact relationship between the three components. Wild type
C57BL6 mice subjected to I/R injury was treated with vehicle, netrin-1,
or netrin-1/UO126 at the onset of reperfusion. The heart was harvested
for NO measurements from the LV. The data, shown on Fig. 6A, demon-
strate that vehicle treated hearts had signiﬁcantly reduced NO bioavail-
ability, while treatment with netrin-1 markedly corrected this
deﬁciency. Co-treatment of netrin-1 and UO126 abolished the beneﬁcial
effects of netrin-1 on NO production, suggesting that activation of
ERK1/2 proceeds eNOS/NO activation.
Furthermore, we measured LV NO production using I/R injured
DCC+/+and DCC+/−mice. The results, shown on Fig. 6B, indicate
that netrin-1 mediated NO increase shown in DCC+/+ animals was
completely abolished in DCC+/−animals. Taken together, these data
conﬁrm that netrin-1 stimulates NO production in I/R injured hearts
through a DCC/ERK1/2/eNOS pathway in vivo.
3.7. Netrin-1 attenuates mitochondrial superoxide production in vivo via
DCC and ERK1/2
Previous studies have shown that the large burst of oxidants in the
mitochondria observed during early reperfusion contributes strongly
to I/R damage [18]. Mice were subjected to a 30 min myocardial
ischemia, injected with vehicle (normal saline); netrin-1 or U0126 (at
same doses described earlier) into the LV at the onset of reperfusion.
The heart was then harvested for mitochondrial isolation and
subsequent ESR detection of superoxide production frommitochondria.
The results, shown in Fig. 7A, illustrate that mitochondria from vehicle
treated hearts produced ~4 times more superoxide after I/R injury
when compared to mitochondria isolated from sham surgery controls.
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Fig. 4. Netrin-1 induced cardioprotection in vivo is ERK 1/2 and NO dependent. Myocardial infarction was induced by a 30 min LCA ligation followed by a 24 h reperfusion. Mice were
injected with either 5 μg/kg netrin-1; 200 μg/kg UO126 alone; 1 mg/kg PTIO alone; 5 μg/kg netrin-1/200 μg/k UO126; or 5 μg/kg netrin-1/1 mg/kg PTIO at the onset of reperfusion.
UO126 was used to inhibit MERK1/2/ERK1/2 activity and PTIO was used to chelate NO speciﬁcally. Cardioprotection elicited by netrin-1 was suppressed in presence of UO126 or PTIO.
Infarct size was analyzed as in Fig. 2. The results were represented as mean ± SEM. ⁎⁎⁎p b 0.001 vs. all others, n= 7/group.
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times, while co-treatment of netrin-1 with UO126 abolished this reduc-
tion, suggesting the role of ERK1/2 in netrin-1mediated reduction in I/R
induced mitochondrial superoxide production.
To examine the role of the DCC receptor in this phenomenon, iden-
tical I/R protocol was performed using DCC+/+and DCC+/−animals.
The results, shown in Fig. 7B, illustrate that netrin-1's effect on
mitochondrial superoxide production was completely abolished in
DCC+/−, implicating a dependency on the DCC receptor.
3.8. Netrin-1 preservation of mitochondrial Integrity in vivo: dependence
on DCC and ERK 1/2
One of themajor events in I/R induced cardiac injury ismitochondri-
al damage and increased superoxide production frommitochondria.We
further examined impact on mitochondrial integrity of netrin-1 by
employing a calcium dependent swelling assay. As shown in Fig. 8A,
netrin-1 perfusion resulted in a marked attenuation of the swelling ac-
tivity, which was reversed by co-treatment with the ERK1/2 inhibitor
UO126. Similar experiments were performed using DCC+/−andDCC+/+ animals. The results, shown in Fig. 8B, indicate that while
netrin-1 is protective of mitochondrial damage in DCC+/+ animals,
DCC+/−animals had a complete loss of the protection. Taken together,
these data indicate that DCC and ERK1/2 are required for mitochondrial
preservation induced by netrin-1 during I/R injury in vivo.
3.9. Netrin-1 down-regulates NOX4 expression and activity in a NO and
ERK1/2 dependent manner
In a previous study using an ex vivomodel of Langendorff perfused
heart, we observed an increase in NOX4 expression and activity from
I/R injured hearts, which was abolished by treatment with netrin-1
[19]. Here, we examined if this also holds true in the in vivo condition
and the signaling pathway involved. Western blots for NOX4 and actin
were performed on hearts treated with vehicle, netrin-1, netrin-1/
PTIO, or netrin-1+U0126 and harvested 30 min after reperfusion.
Fig. 9A and B showed that treatmentwith netrin-1 signiﬁcantly reduced
NOX4 expression in LV, which was reversed by co-treatment with PTIO
and U0126. These results show that netrin-1 reduction of NOX4 is de-
pendent on ERK1/2 and NO. Given that ERK1/2 activation occurs prior
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ERK1/2:eNOS:NO:NOX4 pathway.
To further examine changes in NOX4 activity, we measured NOX4
speciﬁc activity using ESR in the presence of Fulvene-5, an inhibitor
for NOX4 [17]. The results, shown on Fig. 9C, indicate that I/R
signiﬁcantly increased NOX4 activity, while netrin-1 perfusion largely
abrogated this effect. Further, treatment with PTIO, a speciﬁc NO scav-
enger, completely abolished netrin-1's inhibitory effect on NOX4 activa-
tion, again implicating an upstream role of NO in silencing NOX4
pathway of oxidative activation.
3.10. Netrin-1 attenuates autophagy in post-MI remodeled heart
In additional experiments we performed permanent LAD ligation to
inducemyocardial infarction (MI). Chronically, autophagywasmarked-
ly increased in post-MI remodeled heart, whichwas completely attenu-
ated by netrin-1 perfusion (Fig. 10). Microtubule-associated proteins
1A/1B light chain 3, LC3, a mammalian homolog of yeast Atg8, is a
major mediator of autophagy. During autophagy, LC3-I, a cytosolic
form of LC3, is converted into LC3-II which is a speciﬁc marker ofautophagosomes, and the ratio of LC3-II/LC3-I is an established indicator
of autophagy. In this study, we found that LC3-II was up regulated in the
post-MI heart and the myocardial LC3-II/LC3-I ratio was signiﬁcantly
increased in MI animals. However, in mice infused with netrin-1 for
14 days using subcutaneously embedded osmotic minipumps, the
myocardial LC3-II/LC3-I ratio decreased to the level similar to the
sham group.
4. Discussion
Themost signiﬁcantﬁndings of thepresent study are: 1) establishment
of a potent cardioprotective effect of netrin-1 in vivo; 2) establishment
that netrin-1 not only effectively reduces infarct size after I/R injury,
but also markedly improves cardiac function; 3) establishment that
netrin-1 exerts cardioprotection in vivo via preservation of mitochon-
drial integrity that is dependent on a DCC/ERK1/2/eNOS/NO pathway;
4) establishments that netrin-1 attenuates oxidative stress in I/R
injured heart via ERK1/2/NO-mediated downregulation of NOX4 ex-
pression and activity; 5) establishment that in addition to its potent,
acute cardioprotective effects during I/R injury, netrin-1 may also be
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Fig. 6. Netrin-1 induction of NO production in vivo is DCC and ERK 1/2 dependent. Bioavailable NO levels in the left ventricle were determined by electron spin resonance (ESR) frommice
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autophagy. These ﬁndings mechanistically highlight a therapeutic po-
tential of netrin-1 in treating reperfusion dependent or independent
myocardial infarction when delivered to animals in vivo.
Netrin-1 is cardioprotective in vivo when given at modest doses
(Fig. 1). Further, this protective effect is accompanied by improvement
in the physiological function of the heart as measured by ejection frac-
tion and fractional shortening via echocardiography (Fig. 2). While
netrin-1 has been shown by our laboratory in the past to confer
cardioprotection in an ex-vivo model [14], the use of netrin-1 in an
in vivo, physiological setting in thepresent study further conﬁrms its po-
tency and consistency in cardioprotection. The improvement in cardiacA
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The molecular pathway through which netrin-1 exerts
cardioprotection in vivo is thoroughly characterized in this study.
The use of DCC+/− animals (Fig. 3) and inhibitors for ERK1/2 and NO
(Fig. 4) all abolished the cardioprotective effect of netrin-1, which
clearly shows involvement of these signaling mediators. To elucidate
the precise pathway for this protection,we ﬁrst examined phosphoryla-
tion of ERK1/2 and eNOS in DCC+/+ and DCC+/− animals (Fig. 5),
which shows that the activation of both ERK1/2 and eNOS by netrin-1
in DCC+/+ animals is abolished in DCC+/− mice, suggesting thatDCC+/+
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NO (Fig. 6), we observed that inhibition of ERK1/2 with UO126
abolished netrin-1's effect in augmenting NO production in the I/R
injured heart, implicating a dependency of this process on ERK1/2
activation. Taken together, these data clearly show that netrin-1's
cardioprotective mechanism is mediated via a DCC:ERK1/2:eNOS:NO
pathway.
Nitric oxide has been shown in the past to be a powerful
cardioprotective agent against I/R injury [3,20–23], mediating a number
of protective mechanisms such as being anti-oxidative [24,25], anti-
inﬂammatory [26,27], anti-apoptotic [28,29], and anti-detrimental
signaling [30]. A number of agents that have shown cardioprotective
effects against I/R injury take advantage of NO, such as estrogen [31], sil-
denaﬁl [32], and statins [33]. However, these treatments have their own
side effects and limitations. The larger problem is that while at low dose
NOmay be anti-apoptotic, high levels of NO have been shown to be pro-
apoptotic [28,29] and may even contribute to hypotension and sudden
cardiac death [34]. In this study, while the dose of netrin-1 used for op-
timal I/R protection enhancedNO level in the heart (Fig. 6A), it is impor-
tant to note that this enhanced level was still below that of sham
surgery controls, suggesting that this dose is safe for the animals.
However, high dose of netrin-1 had no protective effect (Fig. 1), mech-
anisms of which need to be further elucidated.
Cardiac mitochondria are important not only for maintaining sufﬁ-
cient ATP generation, but also involved in cell death and loss of
cardiomyocytes [35,36]. Opening of the mitochondrial permeability
transition pore (mPTP) leads to cell death, and has been implicated in
ischemic injury and the development and progression of heart failure
[37–40]. A previous study revealed that NO prevents permeability tran-
sition in isolated mitochondria, and reperfusion-induced ROS genera-
tion in the reperfused heart [41]. These studies agree well with the
results of our current study, where netrin-1, which was shown here to
increase NO production, reducesmitochondrial swelling andmitochon-
drial superoxide production (Figs. 7, 8). Co-treatment with UO126, or
experiments using DCC+/− animals, shows that this protective effect
of netrin-1 against mitochondrial damage lies downstream of DCC and
ERK1/2 activation, likely due to DCC/ERK1/2-dependent augmentation
in NO production. In a related report from our laboratory, we have
shown that netrin-1 preserves mitochondrial integrity via NO depen-
dent attenuation of NADPH oxidase isoform 4 (NOX4) activation andeNOS uncoupling ex vivo[42]. In the present study we found that
netrin-1 similarly abolished I/R induced upregulation in NOX4 expres-
sion and activity in vivo. This would represent an important pathway
by which netrin-1 treatment attenuates oxidative stress during I/R
injury.
In additional experiments we employed a permanent LAD ligation
model of MI to examine chronic effects of netrin-1 on autophagy in
post-MI remodeled heart. Autophagy is a fundamental cellular mecha-
nism by which eukaryotic cells degrade and recycle macromolecules
and organelles. In the heart, autophagy performs housekeeping
functions such as maintaining cardiomyocyte structure and function.
However, cardiac autophagy is increased in response to oxidative stress,
ATP depletion and mPTP opening [43,44]. Of note, such metabolic
changes are involved in both I/R and post-MI remodeling, and previous
studies have shown that signiﬁcantly increased cardiac autophagy is ob-
served during I/R [43,45], and post-MI remodeling [46,47]. In this study,
by employing a permanent LAD ligation model of MI, we consistently
found that cardiac autophagy, assessed by the ratio of LC3-II to LC3-I,
was dramatically upregulated in the post-MI remodeled heart, and
this response was completely attenuated by netrin-1 infusion. These
data indicate that netrin-1 might be highly protective chronically as
well, via modulation of autophagy-dependent post-MI remodeling. Of
note, the limitation of the study here is the employment of a permanent
MI model rather than a more acute I/R model. However our hypothesis
was that autophagy might be much more importantly modulated by
netrin-1 during the chronic process to limit excessive remodeling of
heart and enable better repair.
In summary, this study clearly illustrates that netrin-1 effectively
protects the heart from I/R injury in vivo, when delivered intraventricu-
larly or intravenously via tail vein. This is mediated by DCC dependent
ERK1/2/eNOS activation and NO production, and subsequent preserva-
tion of mitochondrial integrity that is essential for the survival of
cardiomyocytes and the improved cardiac function. These results here
establish netrin-1 as a potent therapeutic agent against I/R injury and
elucidated several novel mechanisms to this function. In addition to
this therapeutic application to acute MI, netrin-1 may also be beneﬁcial
in treating post-MI remodeling of the heart chronically, together
making netrin-1 a particularly valuable therapeutic option for MI
management.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.06.005.
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